Cellular Senescence-Inducing Small Molecules for Cancer Treatment.

Research paper by Peng P Liu, Yanfang Y Wu, Ziwen Z Lu, Dongsheng D Shang, Zhicong Z Zhao, Yanting Y Shen, Yafei Y Zhang, Feifei F Zhu, Hanqing H Liu, Zhigang Z Tu

Indexed on: 01 Jun '18Published on: 01 Jun '18Published in: Current cancer drug targets


Recently, the chemotherapeutic drug-induced cellular senescence is considered per se a promising anti-cancer approach. This drug-induced senescence, which shows both similar, and different hallmarks from replicative senescence and oncogene-induced senescence, was regarded as a key determinant of tumor response to chemotherapy in vitro and in vivo. To date, plenty of effective chemotherapeutic drugs that evoke senescence in cancer cells have been reported. The targets of these drugs differ substantially from each other, as well as from DNA damage response, telomerase activity inhibition through senescence-related CDK, p53 and Rb signaling pathways. The purpose of this review is to summarize these senescence-targeting small-molecular drugs and remark their specific traits and corresponding mechanisms that offer novel perspectives in cancer therapy. We collected information and data from manuscripts, publications and online database. In this review, 50 senescence-targeting small-molecular drugs were summarized with emphasis on their molecular structures, targets/mechanisms as well as the effects for inducing senescent phenotype in certain cancer cell lines. To date, plenty of effective small-molecular chemotherapeutic drugs were exploited to evoke cellular senescence in cancer therapy through different mechanisms and pathways. Insight into the mechanisms and signaling pathways of these senescence-targeting chemotherapeutic drugs will facilitate the successful treatment of cancers in clinic. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.